Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Diffuse Intrinsic Pontine Glioma 1Cut-Off Value 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

Temozolomide 3Specimen Handling 2tovorafenib 1spartalizumab 1ribociclib 1pembrolizumab 1lutetium Lu 177 dotatate 1larotrectinib 1balstilimab 1Vaccines 1Receptors, Interleukin-8B 1Radiotherapy 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1PTC596 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Injections 1Immune Checkpoint Inhibitors 1Fluid Therapy 1Everolimus 1Eflornithine 1Diphtheria-Tetanus Vaccine 1Diffusion Tensor Imaging 1Cilengitide 1CLR1404 1CBLC137 1Biopsy 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × Fluid Therapy × 90 days × Clear all
NCT04870944 2026-05-05

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Children's Oncology Group

Phase 1/2 Recruiting
63 enrolled
CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡